In patients with asymptomatic LVSD as a result of a previous MI, we found that the addition of a neprilysin inhibitor to RAS inhibition with sacubitril/valsartan, compared with RAS inhibition alone with valsartan, did not lead to significant favorable changes in LV or atrial volumes, LVEF, and biomarkers of LV wall stress (NT-proBNP) or myocardial damage (high-sensitivity cardiac troponin I). The gene discussed is TNNI3; the disease is myocardial infarction.